Japan’s evolving approach to market access includes a formal cost-effectiveness analysis (CEA) requirement for certain new ...

Eli Lilly has shared positive top-line results from a head-to-head study of its non-covalent Bruton’s tyrosine kinase (BTK) ...

AstraZeneca (AZ) has announced that Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) has been recommended by ...

Patient activation is people’s knowledge, skills, confidence and willingness to manage their own health and care. Increasing ...

Bristol Myers Squibb (BMS) and Bain Capital have created an independent biopharmaceutical company to develop immunology ...

The European Medicines Agency’s human medicines committee has recommended that BeOne Medicines’ Tevimbra (tislelizumab) be ...

But while an improved reputation can be a by-product of patient engagement, it should not be the driving force behind it.

Biogen’s Qalsody (tofersen) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the first ...

Rezpegaldesleukin, which has already been granted FDA fast track designation for moderate-to-severe atopic dermatitis, is ...

Inclusion isn’t just about eligibility; it’s about participation Trials often demand time, travel and flexibility, resources ...

Discover how patient-centred design transforms inclusive clinical trials. Learn to overcome trial recruitment challenges by ...